Cover Image
Market Research Report
Product code 
1034316

Ayvakit Patent, Sales & Clinical Trials Insight 2028

Published: | KuicK Research | 85 Pages | Delivery time: 1-2 business days

Price

Back to Top
Ayvakit Patent, Sales & Clinical Trials Insight 2028
Published: October 27, 2021
KuicK Research
Content info: 85 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

“Ayvakit Patent, Sales & Clinical Trials Insight 2028 ” Report Analysis & Data Highlights:

  • Ayvakit Patent Insight
  • Ayvakit Dosage & Price
  • Ayvakit Sales Forecast 2028: > USD 1 Billion
  • Ayvakit Role in Cancer Therapy
  • Ayvakit Structure & Pharmacokinetics Properties
  • Ayvakit Ongoing Clinical Trials: > 10 Clinical Studies
  • Ayvakit Reimbursement Scenario

Avapritinib (formerly BLU-285) developed by Blueprint Medicines Corporation is a selective and potent inhibitor of KIT and PDGFRA that shows activity against resistance mutations in the activation loop of each kinase (exons 17/18 and exon 18, respectively) in addition to other well-characterized disease-driving KIT mutants. The drug is sold under the brand name Ayvakit (US)/ Ayvakyt (Europe). Initially, the drug was granted orphan status by US FDA. However in January 2020, US FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. In June 2021, the drug was further granted approval for the treatment of adult patients with advanced systemic mastocytosis (Advanced SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL).

Apart from US, the drug was also granted approval by European Commission in 2020. In China, the drug was market by Cstone Therapeutics and was recently granted approval in 2021 for the management of GIST only. The rapid approval of the drug in different regions of the world will propel the market during the forecast period. Owing to its specific mechanism of action, it has been shown that the drug Ayvakit has superior efficacy than approved drugs of this class. In addition, it has the ability to overcome the limitations of other conventional cancer therapies which will further boost the growth of market.

Apart from approved indications, several ongoing studies are evaluating the role of Ayvakit in the management of other cancers including colorectal cancer, breast cancer, lung cancer, melanoma, and others. The majority of these studies are present in phase-II clinical trials. Therefore, our report suggests that coming years will witness extended approval of drug in wide range of cancers, which will boost the market growth. In addition, the drug will not face any competition from generic drug, which will also have a positive impact on the growth of market.

Despite several favorable parameters, the overall market will mainly be restricted by high cost of therapy, long duration of drug development, and stringent regulatory norms. However, advancement in the field of science and innovation has led to the development of new technologies which will ease the drug designing process. Moreover, rising initiatives by government and pharmaceutical giants has led to development of favorable reimbursement policies which enhance their uptake in market. For instance, YourBlueprint program was initiated to provide coverage for patients using Ayvakit.

Keeping in mind the sales in previous years and ongoing clinical trials, the report analyzes that the global sales will reach US$ 1 Billion by 2028. The overall market for PDGFR inhibitor is highly competitive and includes several potential candidates in development pipelines. The rapid approval of drugs from this class will have a negative impact on the growth of Ayvakit market. Geographically, US will continue to dominate the market owing to high adoption rates of approved Ayvakit. In addition, the presence of well-developed technology, increase patient base, robust research and development activities, and high investment in the healthcare sectors is aiding to promote the growth of market in the region.

Table of Contents

1. Ayvakit (Avapritinib) - Approval & Patents

  • 1.1. Overview
  • 1.2. Patents & Assignees

2. Ayvakit Commercial Insight

  • 2.1. Price & Dosage
  • 2.2. Sales Analysis

3. Ayvakit Mechanism of Action

4. Ayvakit Role in Cancer

5. Ayvakit Role in Other Therapeutic Indications

6. Ayvakrit Supplementary Information

  • 6.1. Use in Specific Population
  • 6.2. Adverse Reactions
  • 6.3. Drug Interactions

7. Ayvakit Structure & Pharmacokinetics Properties

8. Global Ayvakit Market Analysis

9. Ayvakit Future Market Opportunity by Indication

  • 9.1. Gastrointestinal Tumors
  • 9.2. Mastocytosis
  • 9.3. Lung Cancer
  • 9.4. Colorectal Cancer

10. Ayvakit Sales Forecast 2028

11. Ayvakit Clinical Trial Insights

  • 11.1. By Phase
  • 11.2. By Region
  • 11.3. By Status
  • 11.4. Ongoing Clinical Trials

12. Ayvakit Reimbursement Scenario

13. Competitive Landscape

  • 13.1. Arog Pharmaceuticals
  • 13.2. AstraZeneca
  • 13.3. Bayer
  • 13.4. Blueprint Medicine
  • 13.5. Boehringer Ingelheim
  • 13.6. Clovis Oncology
  • 13.7. Deciphera Pharmaceuticals
  • 13.8. Eli Lilly
  • 13.9. Gilead Sciences
  • 13.10. Pfizer
  • 13.11. Tyrogenex
  • 13.12. Zai Lab

List of Figures

  • Figure 1-1: Ayvakit - US & Europe Orphan Drug Designation Approval
  • Figure 1-2: US - Ayvakit FDA Approval Year by Indication
  • Figure 1-3: Ayvakit - Approval Year by Region
  • Figure 1-4: US - Avyakit Patent Approval & Expiration Year
  • Figure 2-1: US - Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet (US$), October'2021
  • Figure 2-2: Europe - Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet (Euro/US$), October'2021
  • Figure 2-3: Ayvakit - Recommended Initial & Minimum Dose by Indication (mg/day)
  • Figure 2-4: Ayvakit - Recommended Initial & Reduced Dose in Patients with GIST (mg/day)
  • Figure 2-5: Ayvakit - Recommended Initial & Reduced Dose in Patients with Mastocytosis (mg/day)
  • Figure 2-6: US - Average Cost of Daily, Monthly & Annual Treatment with Ayvakit (US$)
  • Figure 2-7: Global - Ayvakit Quarterly Sales (US$ Million), 2020
  • Figure 2-8: Global - Ayvakit Quarterly Sales (US$ Million), Q1 & Q2'2021
  • Figure 3-1: PDGFR's Pathway, Receptors, Ligands & Functions
  • Figure 3-2: PDGFR Stimulated Effectors, Biomarkers & Cell Signaling Pathways
  • Figure 3-3: PDGFR Inhibitors - Mechanism of Action
  • Figure 3-4: Ayvakit - Mechanism of Action
  • Figure 4-1: PDGF Signaling in Cancer Progression
  • Figure 5-1: Role of PDGFR Inhibitors in Neurological Disorders
  • Figure 5-2: Potential Role of PDGFR Inhibitors in Asthma
  • Figure 7-1: Ayvakit - Chemical Structure
  • Figure 8-1: Global - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 8-2: Global - PDGFR Inhibitor Market by Product (US$ Million), 2020
  • Figure 8-3: Global - PDGFR Inhibitor Market by Product (%), 2020
  • Figure 8-4: Global - PDGFR Inhibitor Market by Product (US4 Million), H1'2021
  • Figure 8-5: Global - PDGFR Inhibitor Market by Product (%), H1'2021
  • Figure 9-1: Global - Estimated GIST Cancer Cases, 2021 - 2028
  • Figure 9-2: Global - Ayvakit Market Opportunity in GIST by 2% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-3: Global - Ayvakit Market Opportunity in GIST by 4% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-4: Global - Ayvakit Market Opportunity in GIST by 6% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-5: Global - Ayvakit Market Opportunity in GIST by 8% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-6: Global - Ayvakit Market Opportunity in GIST by 10% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-7: Global - Ayvakit Market Opportunity in GIST by 12% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-8: Global - Ayvakit Market Opportunity in GIST by 14% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-9: Global - Ayvakit Market Opportunity in GIST by 16% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-10: Global - Ayvakit Market Opportunity in GIST by 18% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-11: Global - Ayvakit Market Opportunity in GIST by 20% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-12: Global - Estimated Systemic Mastocytosis Cases, 2021 - 2028
  • Figure 9-13: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 2% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-14: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 4% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-15: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 6% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-16: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 8% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-17: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 10% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-18: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 12% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-19: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 14% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-20: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 16% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-21: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 18% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-22: Global - Ayvakit Market Opportunity in Systemic Mastocytosis by 20% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-23: Global - Estimated Lung Cancer Cases, 2021 - 2028
  • Figure 9-24: Global - Estimated PDGFR Mutated Lung Cancer Cases, 2021 - 2028
  • Figure 9-25: Global - Ayvakit Market Opportunity in Lung Cancer by 1% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-26: Global - Ayvakit Market Opportunity in Lung Cancer by 2% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-27: Global - Ayvakit Market Opportunity in Lung Cancer by 3% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-28: Global - Ayvakit Market Opportunity in Lung Cancer by 4% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-29: Global - Ayvakit Market Opportunity in Lung Cancer by 5% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-30: Global - Estimated Colorectal Cancer Cases, 2020-2028
  • Figure 9-31: Global - Estimated Metastatic Colorectal Cancer Cases, 2020-2028
  • Figure 9-32: Global - Ayvakit Market Opportunity in Colorectal Cancer by 1% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-33: Global - Ayvakit Market Opportunity in Colorectal Cancer by 2% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-34: Global - Ayvakit Market Opportunity in Colorectal Cancer by 3% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-35: Global - Ayvakit Market Opportunity in Colorectal Cancer by 4% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-36: Global - Ayvakit Market Opportunity in Colorectal Cancer by 5% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-37: Global - Ayvakit Market Opportunity in Colorectal Cancer by 6% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-38: Global - Ayvakit Market Opportunity in Colorectal Cancer by 7% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-39: Global - Ayvakit Market Opportunity in Colorectal Cancer by 8% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-40: Global - Ayvakit Market Opportunity in Colorectal Cancer by 9% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 9-41: Global - Ayvakit Market Opportunity in Colorectal Cancer by 10% Adoption Rate (US$ Million), 2021 - 2028
  • Figure 10-1: Global - Ayvakit Sales Forecast (US$ Million), 2021 - 2028
  • Figure 11-1: Avapritinib - Number of Clinical Trials by Phase, October'2021
  • Figure 11-2: Avapritinib - Number of Clinical Trials by Phase (%), October'2021
  • Figure 11-3: Avapritinib - Number of Clinical Trials by Region, October'2021
  • Figure 11-4: Avapritinib - Number of Clinical Trials by Status, October'2021
  • Figure 11-5: Avapritinib - Number of Clinical Trials by Status (%), October'2021
  • Figure 11-6: Ayvakit - Start & Completion Year of Avapritinib in Adult Solid Tumors
  • Figure 11-7: Ayvakit - Start & Completion Year of Avapritinib in Pediatric Solid Tumors
  • Figure 11-8: Ayvakit - Start & Completion Year of Avapritinib in GIST
  • Figure 11-9: Ayvakit - Start & Completion Year of Drug-Drug Interaction
  • Figure 12-1: Ayvakit - Total Treatment Cost & Reimbursement Cost
  • Figure 12-2: Ayvakit - In Pocket & Out of Pocket Cost of Treatment